Testing flazoparib with temozolomide after standard treatment for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial is for people with newly diagnosed glioblastoma who have finished standard chemoradiation. It tests whether adding a drug called flazoparib to the usual chemotherapy (temozolomide) can help prevent the cancer from coming back. Researchers will check safety and how well the combination works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have newly diagnosed glioblastoma and have completed standard chemoradiation (radiation and temozolomide together).
- At least 80% of your tumor was surgically removed (not just a biopsy).
- Your overall health status (Karnofsky score) is 60 or higher, meaning you can care for most daily needs.
- Your blood counts and liver/kidney function must be within certain safe ranges (checked by a blood test).
- You must agree to use highly effective birth control if you or your partner could become pregnant, for the duration of the study and 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two drugs—vebreltinib and temozolomide—for people with a type of brain cancer called glioblastoma. It is for those who have already had surgery to remove as much of the tumor as possible.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.